Drug Trial Radar · NCT04170283
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
955
Actual
Start
Jan 16, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study. Participants continued receiving zanubrutinib if they were still benefiting from it, or they might have taken part in long-term follow-up after treatment. Information collected in this study will help health authorities better understand the long-term effects of zanubrutinib.
Conditions
- B-cell Malignancies
Interventions
ZanubrutinibDrug
Participants will receive a total dose of 320 mg daily, given either as 160 mg BID or 320 mg QD, or the last dose level received in the sponsor parent study.
TislelizumabDrug
Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 5 years
Locations
153 sites in 18 countries. Site status is shown where the registry gives one.
Banner Md Anderson Cancer Center
Gilbert, Arizona
Carti Cancer Center
Little Rock, Arkansas
Rocky Mountain Cancer Centers Centennial
Centennial, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
Florida Cancer Specialists Fort Myers
Fort Myers, Florida
Scri Florida Cancer Specialists North
St. Petersburg, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Forrest General Hospital Cancer Center
Hattiesburg, Mississippi
University of Nebraska Medical Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Summit Medical Group
Florham Park, New Jersey
Atlantic Health System
Morristown, New Jersey
Optum Medical Care, Pc.
Westbury, New York
Duke University Hospital
Durham, North Carolina
Oncology Associates of Oregon Willamette Valley Cancer Center
Eugene, Oregon
Oregon Health and Science University
Portland, Oregon
Scri Tennessee Oncology Chattanooga
Chattanooga, Tennessee
Tennessee Oncology
Nashville, Tennessee
Texas Oncology Fort Worth Cancer Center
Fort Worth, Texas
The University of Texas Md Anderson Cancer Center
Houston, Texas
Texas Oncology San Antonio Medical Center Usor
San Antonio, Texas
Oncology and Hematology Associates of Southwest Virginia, Inc
Roanoke, Virginia
University of Washington Seattle Cancer Alliance
Seattle, Washington
Medical Oncology Associates
Spokane, Washington
Paratus Clinical Research Woden
Canberra, Australian Capital Territory, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Border Medical Oncology
East Albury, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Princess Alexandra Hospital
Brisbane, Queensland, Australia
Brisbane Clinic For Lymphoma
Greenslopes, Queensland, Australia
John Flynn Private Hospital
Tugun, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Flinders Medical Centre
Bedford PK, South Australia, Australia
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.